Quick Answer
Cellectar Biosciences, Inc. reported R&D Expense of $11.50 million for fiscal year 2025.
Cellectar Biosciences, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $11.50M | -56.0% |
| 2024 | $26.14M | -4.1% |
| 2023 | $27.27M | +41.9% |
| 2022 | $19.22M | +9.3% |
| 2021 | $17.59M | +73.4% |
| 2020 | $10.14M | +12.7% |
| 2019 | $9.00M | +31.6% |
| 2018 | $6.84M | -27.8% |
| 2017 | $9.47M | +99.3% |
| 2016 | $4.75M | -7.9% |
| 2015 | $5.16M | -13.5% |
| 2014 | $5.96M | -13.1% |
| 2013 | $6.86M | +33.9% |
| 2012 | $5.12M | +42.3% |
| 2011 | $3.60M | +20.6% |
| 2010 | $2.98M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.52M | -54.1% | +5.6% |
| June 30, 2025 | $2.39M | -67.5% | -30.3% |
| March 31, 2025 | $3.43M | -51.6% | -37.6% |
| September 30, 2024 | $5.49M | -21.9% | -25.2% |
| June 30, 2024 | $7.35M | +19.7% | +3.6% |
| March 31, 2024 | $7.09M | +6.5% | +0.8% |
| September 30, 2023 | $7.03M | +30.8% | +14.7% |
| June 30, 2023 | $6.14M | +36.4% | -7.8% |
- Cellectar Biosciences, Inc. showed a decrease of -56.0% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, Cellectar Biosciences, Inc.’s r&d expense has grown by 285.3% (from $2.98 million to $11.50 million).
- The most recent figure is from Cellectar Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: